Thoratec Corp. (THOR)
-NasdaqGS | Prev Close: | 31.49 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 39.00 |
|---|
| Beta: | 0.78 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 29.39 - 39.86 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 652,514 |
|---|
| Market Cap: | 1.81B |
|---|
| P/E (ttm): | 38.36 |
|---|
| EPS (ttm): | 0.82 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- FDA Nod for Thoratec ControllerZacks(Mon, May 20)
- Thoratec Is Now Oversold (THOR)at TheStreet(Mon, May 20)
- Value Investors Take Note: Fire Sale On This Heart Failure Assetat Seeking Alpha(Mon, May 20)
- 3 Healthcare Stocks Stories To Close Out the Trading Weekat Wall St. Cheat Sheet(Fri, May 17)
- Medical Products Companies, Particularly Those Aimed at Surgical Procedures, Generating Substantial Free Cash and Showing High Returns on CapitalWall Street Transcript(Fri, May 17)
- Ford Migrates Fiesta Production, Thoratec Gets FDA Approval, and 3 More Hot Stocksat Wall St. Cheat Sheet(Fri, May 17)
- Thoratec Announces FDA Approval Of HeartMate II® Pocket Controller™PR Newswire(Fri, May 17)
- Thoratec Presentation At Bank of America Merrill Lynch 2013 Health Care Conference To Be WebcastPR Newswire(Tue, May 14)
- 1 Reason Thoratec May Be Headed for a Slowdownat Motley Fool(Mon, May 13)
- THORATEC CORP FinancialsEDGAR Online Financials(Fri, May 10)
- A Look Into Thoratec's Recent Resultsat Seeking Alpha(Mon, May 6)
- Thoratec Misses Earnings and Rev EstZacks(Mon, May 6)
- Thoratec upgraded to Neutral from Underperform at Credit Suissetheflyonthewall.com(Mon, May 6)
- Earnings Volatility Drives These Stocks in a New Directionat Wall St. Cheat Sheet(Sat, May 4)
- Thoratec skids on disappointing 1Q resultsAP(Fri, May 3)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| THOR | 0.00% | 1.81B |
| BAX | 0.00% | 39.53B |
| COV | 0.00% | 30.83B |
| CSRT.L | 0.32% | 224.25M |
| BDX | 0.00% | 19.64B |
Key Statistics
| Forward P/E (1 yr): | 15.90 |
|---|
| P/S (ttm): | 3.74 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.78 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.43 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 1.98 |
|---|
Business Summary
Thoratec Corporation engages in the development, manufacture, and marketing of proprietary medical devices used for circulatory support. The companys primary product lines include ventricular assist devices, such as HeartMate II, an implanta...
View More